ea0045oc5.1 | Oral Communications 5- Endocrine | BSPED2016
Padidela Raja
, van't Hoff William
, Hogler Wolfgang
, Portale Anthony
, Imel Erik
, Boot Annemieke
, Linglart Agnes
, Whyte Michael
, Skrinar Alison
, San Martin Javier
, Carpenter Thomas
In XLH, high circulating FGF23 causes hypophosphatemia, rickets, and short stature. In our Phase 2 study, 52 XLH children (ages 512 years, ≤Tanner 2) were randomized to receive KRN23 subcutaneously biweekly (Q2W) or monthly (Q4W). Serum phosphate (Pi) was measured biweekly. KRN23 dose was titrated (maximum 2 mg/kg) targeting age-appropriate serum Pi concentrations.The first 36 subjects had a mean 6.6 years of standard-of-care treatment before...